PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Tacrolimus

Drugs in development · updated 30 October 2026

Tacrolimus: clinical trials and development status

Other names and codes: Envarsus XR, Prograf, Astagraf Xl, Protopic, Advagraf

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 27 February 2002

As of 30 October 2026 Tacrolimus is in 109 active clinical trials (recruiting or ongoing, phases I–III) for 124 diseases. The most advanced phase is III.

109Active trials
IIIMost advanced phase
124Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Tacrolimus and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 124 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Acute myeloid leukemiaIII27NCT05457556
Myelodysplastic SyndromesIII27NCT05457556
Precursor lymphoblastic lymphoma/leukemiaIII19NCT05457556
Graft-versus-host diseaseIII10NCT06615050
Acute biphenotypic leukaemiaIII5NCT05457556
Chronic kidney failureIII3NCT07835581
Congenital AbnormalitiesII–III2NCT02395497
Amyotrophic lateral sclerosisII–III1NCT04302870
Atopic dermatitisIII1NCT06241118
Bronchiolitis obliterans syndromeIII1NCT06615050
Lipoid nephrosisIII1NCT06405100
Liver diseaseIII1NCT07739914
LymphedemaII–III1NCT06306274
Membranous glomerulonephritisIII1NCT07851220
Penis agenesisII–III1NCT02395497
Traumatic amputationII–III1NCT02395497
TremorII–III1NCT03769298
Wounds and InjuriesII–III1NCT02395497
Chronic myelomonocytic leukemiaII11NCT05364762
Myeloproliferative disordersII11NCT06265584
MyelofibrosisII10NCT07228624
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII9NCT06001385
LeukemiaII8NCT07524530
Hematologic neoplasmII7NCT07524530
Non-Hodgkin lymphomaII7NCT02861417
LymphomaII6NCT07524530
Hematologic DiseasesII5NCT06828796
Hodgkin lymphomaII5NCT02861417
Lymphoproliferative disordersII5NCT04339777
Aplastic anemiaII4NCT06412497

Everything on Tacrolimus

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch